Article Details - Overview
Optimizing Cytotoxic Regimens in Advanced Non–Small-Cell Lung Cancer
Oncology Briefings
Release Date: July 24, 2009
Expiration Date: July 24, 2010
Publication Overview
Authors
Medical writer: Aarati Ranganathan, PhD; Reviewed by: Corey Langer, MD, FACP
Overview and Purpose
Many targeted agents have been developed for the treatment of patients with non–small-cell lung cancer (NSCLC); however, lung cancer is a genetically complex set of diseases, and these agents alone are usually not sufficient to control the disease. Consequently, cytotoxic chemotherapy remains an integral part of the treatment of the majority of patients with advanced NSCLC. Newer chemotherapies are being developed to provide optimum benefit and overcome the disadvantages of existing chemotherapeutic formulations. Strategies include the development of novel formulations of taxanes and the investigation of new microtubule inhibitors, such as epothilones, several of which are being investigated in phase III trials.
The purpose of this activity is to apprise physicians of the mechanisms of delivery and action of and clinical data on novel chemotherapeutic drugs in NSCLC.
Target Audience
This educational activity is intended for medical oncologists involved in the care of patients with lung cancer. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.
Learning Objectives
Upon completion of this educational activity, you should be able to:
- Assess the efficacy and adverse event profile of albumin-bound paclitaxel formulations in patients with NSCLC
- Discuss the efficacy and safety of epothilones in patients with previously treated advanced NSCLC
- Evaluate clinical data on poly-L-glutamic acid–conjugated taxanes in NSCLC
Instructions for Participation
- Read the following information before entering the educational activity.
- Complete the Pretest.
- Study the educational activity.
- Complete the Posttest.
- Answer the evaluation questions.
- After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.
You will be permitted 2 attempts to successfully complete the Posttest.
The tests and evaluation must be completed by July 24, 2010, in order for you to receive your certificate.
CME credit will be granted for only 1 form of participation, either online or via the printed publication.
You will be asked to login
or create an account.